- Home
- TNGX vs ESGRP Comparison
TNGX vs ESGRP Comparison
Compare TNGX & ESGRP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TNGX
- ESGRP
- Stock Information
- Founded
- TNGX 2014
- ESGRP N/A
- Country
- TNGX United States
- ESGRP Bermuda
- Employees
- TNGX N/A
- ESGRP 790
- Industry
- TNGX Biotechnology: Pharmaceutical Preparations
- ESGRP Property-Casualty Insurers
- Sector
- TNGX Health Care
- ESGRP Finance
- Exchange
- TNGX Nasdaq
- ESGRP Nasdaq
- Market Cap
- TNGX 351.2M
- ESGRP N/A
- IPO Year
- TNGX N/A
- ESGRP N/A
- Fundamental
- Price
- TNGX $5.88
- ESGRP N/A
- Analyst Decision
- TNGX Strong Buy
- ESGRP
- Analyst Count
- TNGX 6
- ESGRP 0
- Target Price
- TNGX $12.20
- ESGRP N/A
- AVG Volume (30 Days)
- TNGX 2.6M
- ESGRP N/A
- Earning Date
- TNGX 08-06-2025
- ESGRP N/A
- Dividend Yield
- TNGX N/A
- ESGRP N/A
- EPS Growth
- TNGX N/A
- ESGRP N/A
- EPS
- TNGX N/A
- ESGRP N/A
- Revenue
- TNGX $40,990,000.00
- ESGRP N/A
- Revenue This Year
- TNGX N/A
- ESGRP N/A
- Revenue Next Year
- TNGX N/A
- ESGRP N/A
- P/E Ratio
- TNGX N/A
- ESGRP N/A
- Revenue Growth
- TNGX 10.09
- ESGRP N/A
- 52 Week Low
- TNGX $1.03
- ESGRP N/A
- 52 Week High
- TNGX $12.02
- ESGRP N/A
- Technical
- Relative Strength Index (RSI)
- TNGX 73.28
- ESGRP 6.57
- Support Level
- TNGX $5.75
- ESGRP $19.60
- Resistance Level
- TNGX $6.40
- ESGRP $20.48
- Average True Range (ATR)
- TNGX 0.50
- ESGRP 0.52
- MACD
- TNGX -0.03
- ESGRP -1.26
- Stochastic Oscillator
- TNGX 83.80
- ESGRP 0.00
About TNGX Tango Therapeutics Inc.
Tango Therapeutics Inc is a biotechnology company. It is dedicated to discovering novel drug targets and delivering the next generation of precision medicine for the treatment of cancer. It is engaged in the business of discovering and developing precision oncology therapies. It is currently developing two MTA-cooperative PRMT5 inhibitors; TNG462 for non-CNS cancers, including pancreatic and lung cancer, and TNG456, a next-generation, brain-penetrant PRMT5 inhibitor, for CNS cancers, including GBM. Its pipeline products are PRMT5 and CoREST.
About ESGRP Enstar Group Limited Depositary Shares Each Representing 1/1000th of an interest in Preference Shares
Enstar Group Ltd is a (re)insurance group that offers capital release solutions through its network of group companies. It seeks to create value by managing (re)insurance companies and portfolios of (re)insurance and other liability businesses in run-off and striving to generate an attractive risk-adjusted return from its investment portfolio. Its operations are through two reportable segments: Run-off segment and Investments segment.